Nomura Small Cap Core Fund
Delaware Group Equity Funds V · 5 share classes
Fund classification
Classified from what the fund holds · as of 2026 Q2
Nomura Small Cap Core Fund is an actively managed U.S. equity fund. 30% of DCCAX’s stock holdings are in companies whose revenue grew in the top quartile of U.S. companies over the last five fiscal years (covering 93% of the fund’s equity).
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
Fund profile
As filed in the prospectus · 2026 Q1
Nomura Small Cap Core Fund seeks long-term capital appreciation.
The fund invests primarily in stocks of small-capitalization companies—those within the Russell 2000 Index range at purchase—that the manager believes offer attractive valuations, growth prospects, and strong cash flows. At least 80% of net assets will be deployed in small-cap stocks under normal circumstances. Performance will depend on the manager's security selection within this universe.
| Share class | Expense ratio |
|---|---|
| DCCAX | 1.04% |
| DCCCX | 1.79% |
| DCCRX | 1.29% |
| DCCIX | 0.79% |
| DCZRX | 0.69% |
Portfolio turnover 26.00% · as of 2026 Q1
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.19% |
| Cash & short-term | 0.86% |
Sector allocation
The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2
| Industrials | 20.1% |
| Financials | 17.7% |
| Health Care | 16.6% |
| Information Technology | 13.6% |
| 10 smaller | 31.9% |
Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).
Portfolio growth profile
How much of the fund’s stock holdings are in fast-growing companies · as of 2026 Q2
Share of the fund’s equity (by value) in companies whose trailing five-year revenue — or net-income — growth ranks in the top 25% of U.S. public companies. Foreign and newly-listed holdings are excluded, so the figure covers only part of the book. From SEC filings — not investment advice. How we measure this.
Latest quarter
What changed since the fund's previous filing
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
| Share class | 1-year | 3-year | 5-year | Vol | Worst fall |
|---|---|---|---|---|---|
| +29.91% | +42.00% | +25.65% | 14.09% | -18.64% | |
| +28.94% | +38.79% | +20.98% | 14.15% | -18.88% | |
| +29.62% | +40.94% | +24.08% | 14.16% | -18.74% | |
| +30.20% | +43.10% | +27.13% | 14.10% | -18.55% | |
| +30.37% | +43.48% | +27.88% | 14.13% | -18.54% |
These classes hold the same portfolio, so the 6.90pp spread over 5 years is the cost difference between them — roughly 1.38pp a year — not a difference in what they own.
May 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| SMTC | SEMTECH CORPSMTC | 4.04% | $152.54 | $222.88M | 1.5M |
| MYRG | MYR GROUP INCMYRG | 2.02% | $465.06 | $111.38M | 239.5K |
| MOD | MODINE MANUFACTURING COMPANYMOD | 1.98% | $278.91 | $109.46M | 392.5K |
| AXSM | AXSOME THERAPEUTICS INCAXSM | 1.83% | $234.48 | $100.89M | 430.3K |
| TVTX | TRAVERE THERAPEUTICS INCTVTX | 1.78% | $47.18 | $98.42M | 2.1M |
| — | CREDO TECHNOLOGY GROUP HOLDING LTD | 1.76% | $236.03 | $97.35M | 412.5K |
| SLAB | SILICON LABORATORIES INCSLAB | 1.65% | $217.60 | $91.06M | 418.5K |
| LGND | LIGAND PHARMACEUTICALS INCLGND | 1.62% | $231.96 | $89.37M | 385.3K |
| ACA | ARCOSA INCACA | 1.56% | $126.75 | $85.86M | 677.4K |
| ESE | ESCO TECHNOLOGIES INCESE | 1.54% | $291.90 | $84.92M | 290.9K |
Reported price is the fund's own reported value divided by its own reported shares at 2026-05-29 — not a live quote, and not what the fund paid.
Top 10 positions are 19.79% of net assets, top 25 38.75%, across 137 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free